ReviewActa diabetologica2026
Circulating microRNAs as diagnostic biomarkers and pathogenic mediators in type 2 diabetic retinopathy: a systematic review.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs: A Social Network in Diabetic Retinopathy.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review synthesizes current evidence on circulating microRNAs (miRNAs) associated with diabetic retinopathy (DR) in individuals with type 2 diabetes (T2D). DR is a leading cause of vision impairment among adults with diabetes. Identifying circulating miRNAs as minimally invasive biomarkers could enable early DR detection, improve disease monitoring, and support therapeutic development.
methodsFollowing PRISMA guidelines, PubMed and Scopus were systematically searched for English-language studies published between January 2014 and 20 July 2024. Observational studies reporting quantitative expression data (fold-change) of circulating miRNAs in serum or plasma samples from patients with DR and T2D controls were included. Data extraction and quality assessment were independently performed by two reviewers.
resultsFrom 957 screened records, 16 studies met all inclusion criteria. Most studies were conducted in Chinese cohorts and collectively identified numerous differentially expressed miRNAs implicated in NF-κB signaling, PI3K/Akt signaling, angiogenesis, and neuronal apoptosis. Several miRNAs, including hsa-miR-155, hsa-miR-320a, hsa-miR-320b and hsa-miR-338-3p showed consistent dysregulation across multiple studies and demonstrated promise as non-invasive biomarkers for DR diagnosis and progression monitoring. However, heterogeneity in study design, small sample sizes, and limited validation experiments reduced comparability across studies.
conclusionCurrent evidence supports the potential of circulating miRNAs as biomarkers for early detection and monitoring of DR in T2D. Nevertheless, larger, multiethnic, and longitudinal studies with standardized protocols, coupled with mechanistic and functional validation, are essential to confirm their diagnostic and therapeutic utility.
Indexed as
Identifiers
42455341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.